ClinicalTrials.gg
CompletedNCT05795803Updated Apr 3, 2023

Effects of COVID-19 Forced Isolation Context on Adolescents With and Without Somatic Symptom Disorder

An observational study in Somatic Symptom Disorder, sponsored by IRCCS Burlo Garofolo. Completed at 1 site in Italy. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by IRCCS Burlo Garofolo · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
115
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate whether a forced isolation context (such provided by the ongoing Covid-19 pandemic restrictive measures) could reduce the burden of somatic symptoms among a group of patients with Somatic Symptom Disorder (SSD). Secondary objective is to assess if a reduction in terms of depression tendency and anxiety occurs in this specific population and which are the effect of such a context among a group of adolescents without SSD. We want to compare these results with data obtained at the end of the pandemic.

Read the detailed description

This study aims to evaluate whether the forced isolation context provided by the ongoing Covid-19 pandemic is providing an advantage in terms of reduction of somatic symptoms burden among an Italian group of adolescents with SSD, assessed by the Patient Health Questionnaire (PhQ15) administered during and at the end of the pandemic.

Secondary objectives of the study are:

  • To investigate the difference in anxiety and depression scores assessed by the Multidimensional Anxiety Scale for Children (MASC2) and Child Development Inventory (CDI-2) questionnaires among a group of SSD adolescents, during and after the pandemic isolation context.
  • To investigate the difference in anxiety and depression scores assessed by the Multidimensional Anxiety Scale for Children (MASC2) and Child Development Inventory (CDI-2) questionnaires among a group of adolescents without SSD, during and after the pandemic isolation context.
  • To compare the difference in anxiety and depression scores time modification between the two groups of adolescents.
  • To explore through tailored questions which adolescents' coping strategies are during a pandemic isolation context among SSD patients and a group of controls without SSD.
02

Conditions studied

  • Somatic Symptom Disorder

Keywords

  • SSD
  • adolescents
  • coping strategies
  • social media
03

In context

Medically Unexplained Symptoms

71 studies on the registry are indexed under Medically Unexplained Symptoms; 22 are open to participants now.

This study's enrollment of 115 is below the median of 300 across 17 observational studies indexed under Medically Unexplained Symptoms.

Browse Medically Unexplained Symptoms studies →

Lead sponsor

IRCCS Burlo Garofolo is the lead sponsor of 89 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • SSD group: Adolescents who received a diagnosis of SSD at the Institute for maternal and child health "Burlo Garofolo"
  • Without SSD group: Adolescents who accessed the Emergency Department for traumatic injuries or the Pediatric Clinic/Day Hospital Service for oral immunotherapy because of food allergies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescents aged between 12 and 17 years old who received a diagnosis of SSD within the last six months or before unless assessed and confirmed by a specialist within the last six months
  • Adolescents without a diagnosis of SSD, who previously accessed the Institute for maternal and child health "Burlo Garofolo" Emergency Department for traumatic injuries or the Pediatric Clinic/Day Hospital Service for oral immunotherapy because of food allergies.
  • Adolescents experiencing a quarantine period during the Covid19 pandemic.

Exclusion criteria

Exclusion Criteria:

  • Adolescents with cognitive impairment.
  • Adolescents with chronic diseases.
  • Adolescents with other neuropsychiatric disorders according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorder (DSM V).
  • For the group without SSD diagnosis, any access to Emergency Department for unexplained chronic pain or any history of other psychiatric comorbidities.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
115 participants (actual)
Patient registry
No

Groups and cohorts

  • SSD group

    Adolescents with SSD diagnosis made within previously six months or before unless assessed and confirmed by a specialist within the last six months

    Other: Forced isolation context

  • Without SSD group

    Control group: adolescents without diagnosis of SSD, matched with the SSD group by age and sex

    Other: Forced isolation context

Interventions

  • OtherForced isolation context

    Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures

    Also known as: COVID-19 lockdown

06

What researchers measure

Primary outcomes

  1. Difference in mean PhQ15 scale scores between T0 and T1 in the SSD adolescents group.

    To SSD group, the Health Questionnaire Physical Symptoms (PhQ15) will be administrated to quantify the somatic symptom burden.

    Time frame: During the pandemic and within 6 months after the end

Secondary outcomes

  1. Difference in mean MASC2 scores between T0 and T1 in the SSD group.

    SSD adolescents will receive the Multidimensional Anxiety Scale for Children (MASC 2), composed by 50 items, to quantify adolescents' anxiety.

    Time frame: During the pandemic and within 6 months after the end

  2. Difference in mean CDI-2 short questionnaire scores between T0 and T1 in the SSD group.

    SSD adolescents will receive the Children's Depression Inventory (CDI-2) self-report short questionnaire, composed by 12 items, to quantify adolescents' depression.

    Time frame: During the pandemic and within 6 months after the end

  3. Difference in mean MASC2 scores between T0 and T1 in the adolescents group without SSD diagnosis.

    Adolescents without SSD will receive the Multidimensional Anxiety Scale for Children (MASC 2), composed by 50 items, to quantify adolescents' anxiety

    Time frame: During the pandemic and within 6 months after the end

  4. Difference in mean CDI-2 short questionnaires scores between T0 and T1 in the adolescents group without SSD diagnosis.

    Adolescents without SSD will receive the Children's Depression Inventory (CDI-2) self-report short questionnaire, composed by 12 items, to quantify adolescents' depression

    Time frame: During the pandemic and within 6 months after the end

  5. Comparison between the two groups of adolescents in the mean T1-T0 differences for MASC2 scores.

    Differences in the Multidimensional Anxiety Scale for Children (MASC 2), composed by 50 items

    Time frame: During the pandemic and within 6 months after the end

  6. Comparison between the two groups of adolescents in the mean T1-T0 differences for CDI-2 short questionnaires scores.

    Differences in Children's Depression Inventory (CDI-2) self-report short questionnaire, composed by 12 items

    Time frame: During the pandemic and within 6 months after the end

  7. Description of adolescents' coping strategies during a pandemic isolation context among SSD and non-SSD adolescent

    A general anonymous semi-structured survey will be administered to both the groups in order to investigate their habits, social media and videogames pattern of usage, and other leisure pattern of frequency. This will provide us a description of adolescents' general coping strategies during quarantine period.

    Time frame: During the pandemic

07

Study locations

1 site
  • Institute for Maternal and Child Health - IRCCS Burlo Garofolo-
    Trieste, 34137, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05795803
Lead sponsor
IRCCS Burlo Garofolo
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Apr 1, 2020
Primary completion
May 31, 2020
Completion
May 31, 2020
Last update
Apr 3, 2023

Study contacts

Giuseppe Abbracciavento, MD
study chair · Institute for maternal and child health Burlo Garofolo
Laura De Nardi, MD
principal investigator · Institute for maternal and child health Burlo Garofolo
Andrea Trombetta, MD
principal investigator · Institute for maternal and child health Burlo Garofolo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion